Inogen, Inc. INGN announced preliminary revenues for the fourth quarter and full year 2024 on Monday. Following the robust ...

In October this year, the company commenced the US market release of the ‘Inogen Rove 4 Portable Oxygen Concentrator’. The Rove 4 incorporates the company’s patented pulse-dose Intelligent ...

Stifel Nicolaus analyst Mathew Blackman maintained a Hold rating on Inogen (INGN – Research Report) yesterday and set a price target of ...

Inogen, Inc. is a medical technology company, which engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to ...

Jane Street Group LLC trimmed its holdings in Inogen, Inc. (NASDAQ:INGN – Free Report) by 83.1% during the third quarter, ...

Needham analyst Michael Matson has maintained their neutral stance on INGN stock, giving a Hold rating yesterday.Stay Ahead of the ...

Inogen estimates preliminary, unaudited total revenue for the full year 2024 to be in the range of $334.5 million to $335.5 ...

Inogen, Inc. (NASDAQ: INGN) is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid first-quarter ...

Inogen, Inc. INGN is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid second-quarter 2024 ...